Spero Therapeutics (SPRO) FCF Margin (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly FCF Margin came in at 6148.84% in Q1 2026, up 621697.0% on a YoY basis from N/an in Q1 2025, and up 30506.96% quarter-over-quarter from 20.22% in Q4 2025.
Powered by 
Analysis
Spero Therapeutics (SPRO) FCF Margin (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has reported FCF Margin for 11 consecutive years, with 6148.84% the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin rose 621697.0% year-over-year to 6148.84%; the trailing twelve-month figure through Jun 2026 stood at 41.66% (up 10822.0% YoY), and the FY2025 full-year result was 18.9%, up 2997.0% from the prior year.
- FCF Margin rose to 6148.84% in Q1 2026 per SPRO's latest filing, from 20.22% in the prior quarter.
- Across five years, FCF Margin topped out at 6148.84% in Q1 2026 and bottomed at 1364.09% in Q1 2022.
- Historically, FCF Margin has averaged 137.39% across 5 years, with a median of 47.71% in 2022.
- The sharpest annual moves came in 2022 and 2026: FCF Margin tumbled 115205 bps in 2022, then jumped 621697 bps in 2026.
- Over 5 years, FCF Margin stood at 93.76% in 2022, then sank by 125 bps to 23.79% in 2023, then slumped by 554 bps to 155.55% in 2024, then jumped by 87 bps to 20.22% in 2025, then soared by 30507 bps to 6148.84% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 6148.84%, 20.22%, and 320.14% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 34.70% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 44.00% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 30.39% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 13.35% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -388.28% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 22.62% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 14.91% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -18,629.40% |
| 10 | Spero Therapeutics | 67.82 Mn | 17.05 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 6,148.84% |
| Dec 31, 2025 | -20.22% |
| Sep 30, 2025 | 320.14% |
| Jun 30, 2025 | -124.70% |
| Mar 31, 2025 | -68.13% |
| Dec 31, 2024 | -155.55% |
| Sep 30, 2024 | 94.76% |
| Jun 30, 2024 | -183.82% |
| Mar 31, 2024 | 64.08% |
| Dec 31, 2023 | -23.79% |
| Sep 30, 2023 | 62.48% |
| Jun 30, 2023 | -683.51% |
| Mar 31, 2023 | -621.22% |
| Dec 31, 2022 | 93.76% |
| Sep 30, 2022 | -47.71% |
| Jun 30, 2022 | -1,155.69% |
| Mar 31, 2022 | -1,364.09% |
| Dec 31, 2021 | -996.68% |
| Sep 30, 2021 | -161.62% |
| Jun 30, 2021 | -321.81% |